Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8429094 | Best Practice & Research Clinical Haematology | 2017 | 13 Pages |
Abstract
Induction therapy for acute myeloid leukemia has not changed much since 1973, when the 7Â +Â 3 regimen of cytarabine and daunorubicin was born. Since then, various strategies have been evaluated to improve patient response, including dose intensification, the incorporation of additional agents into the regimen, the development of novel agents, and modified approaches for older patients. Recently, two novel agents, CPX-351 and gemtuzumab ozogamicin, have been approved by the US Food and Drug Administration. This review discusses each of the induction strategies and their impact on patient outcomes.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Selina M. Luger,